Levent Hacisüleyman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Levent Hacisüleyman has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Arzuhan Çeti̇nDağ Çi̇lTaş
Sivas cumhuriyet üniversitesi, Sağlık Hizmetleri Meslek Yüksekokulu
4 shared publications - Ziad Joha
Cumhuriyet University
3 shared publications Burcu Şahi̇nBaş
2 shared publicationsBülent Saraç
Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Türkiye
2 shared publicationsRabia Gökçe Takci
Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Türkiye
2 shared publications- Ahmet Sevki Taskiran
Sivas Cumhuriyet University School of Medicine
1 shared publication
Latest Publications
- Open Access
Effects of Valproate and Deferoxamine on Epileptiform Activity, Oxidative Stress, and Nitric Oxide in a Penicillin-Induced Epilepsy Model
Oxidative and nitrosative stress contribute to epileptogenesis and seizure-related neuronal injury through iron-mediated reactive oxygen species generation and excessive nitric oxide production. This study examined whether combining valproate (VALP) with the iron chelator deferoxamine (DFO) produces additional electrophysiological or biochemical effects in a penicillin-induced model of epileptiform activity. Male Wistar rats were assigned to four groups (n = 7/group): penicillin control, VALP (500 mg/kg), DFO (100 mg/kg), and VALP + DFO. Epileptiform activity was induced by intracortical penicillin and monitored by electrocorticography for 180 min, and spike frequency, spike amplitude, serum and hippocampal total antioxidant status, total oxidant status, oxidative stress index, and nitric oxide levels were measured. VALP, DFO, and their combination significantly reduced spike frequency and amplitude versus penicillin. Although VALP + DFO did not further suppress spike frequency or spike amplitude compared with VALP alone, the combination was associated with selected biochemical differences, including lower serum and hippocampal nitrite/nitrate surrogate levels and higher hippocampal total antioxidant status. These findings suggest that VALP + DFO produces selected, marker-specific biochemical changes beyond VALP monotherapy, without providing additional anticonvulsant efficacy in this acute model. The functional significance of these biochemical changes remains to be established.
Open AccessEffects of Valproate and Deferoxamine on Epileptiform Activity, Oxidative Stress, and Nitric Oxide in a Penicillin-Induced Epilepsy Model
Oxidative and nitrosative stress contribute to epileptogenesis and seizure-related neuronal injury through iron-mediated reactive oxygen species generation and excessive nitric oxide production. This study examined whether combining valproate (VALP) with the iron chelator deferoxamine (DFO) produces additional electrophysiological or biochemical effects in a penicillin-induced model of epileptiform activity. Male Wistar rats were assigned to four groups (n = 7/group): penicillin control, VALP (500 mg/kg), DFO (100 mg/kg), and VALP + DFO. Epileptiform activity was induced by intracortical penicillin and monitored by electrocorticography for 180 min, and spike frequency, spike amplitude, serum and hippocampal total antioxidant status, total oxidant status, oxidative stress index, and nitric oxide levels were measured. VALP, DFO, and their combination significantly reduced spike frequency and amplitude versus penicillin. Although VALP + DFO did not further suppress spike frequency or spike amplitude compared with VALP alone, the combination was associated with selected biochemical differences, including lower serum and hippocampal nitrite/nitrate surrogate levels and higher hippocampal total antioxidant status. These findings suggest that VALP + DFO produces selected, marker-specific biochemical changes beyond VALP monotherapy, without providing additional anticonvulsant efficacy in this acute model. The functional significance of these biochemical changes remains to be established.
- 30 April 2026
- Published by Cumhuriyet University in European Journal of Multidisciplinary Health Sciences
- Vol. 11 (1) , 41-53
Uncovering the Global Landscape of PTZ-Induced Experimental Epilepsy Model Research: A Bibliometric Analysis
Epilepsy is a neurological disorder affecting millions of individuals worldwide and remains a major focus of experimental research. The pentylenetetrazole (PTZ)-induced seizure model is widely used in preclinical epilepsy studies; however, its global research landscape has not been systematically evaluated. In this study, a comprehensive bibliometric analysis of PTZ-related epilepsy publications was conducted to identify research trends, influential contributors, and evolving thematic areas. A total of 1,768 original articles published between January 2000 and October 2023 were retrieved from the Scopus database and analyzed using bibliometric tools, including Biblioshiny and VOSviewer, to assess publication output, citation patterns, authorship, institutional and national productivity, and conceptual structure. The results demonstrated a steady growth in PTZ-related publications over time, with China emerging as the leading contributor in terms of publication volume, while Poland showed a high degree of international collaboration. The most cited study was the work by Baraban et al. investigating PTZ-induced behavioral and neural changes in zebrafish. Epilepsy and Behavior, Epilepsy Research, and Epilepsia were identified as the most productive journals in this field. Keyword and thematic analyses revealed frequently studied topics such as oxidative stress, anticonvulsant activity, and neuroinflammation, along with emerging research interests including brain-derived neurotrophic factor and neuronal damage. This study represents the first bibliometric evaluation specifically focused on the PTZ-induced experimental epilepsy model and provides a comprehensive overview of the global research landscape. The findings may assist researchers in recognizing key contributors, identifying research gaps, and guiding future experimental studies in epilepsy.
- 30 April 2026
- Published by Cumhuriyet University in European Journal of Multidisciplinary Health Sciences
- Vol. 11 (1) , 41-53
Uncovering the Global Landscape of PTZ-Induced Experimental Epilepsy Model Research: A Bibliometric Analysis
Epilepsy is a neurological disorder affecting millions of individuals worldwide and remains a major focus of experimental research. The pentylenetetrazole (PTZ)-induced seizure model is widely used in preclinical epilepsy studies; however, its global research landscape has not been systematically evaluated. In this study, a comprehensive bibliometric analysis of PTZ-related epilepsy publications was conducted to identify research trends, influential contributors, and evolving thematic areas. A total of 1,768 original articles published between January 2000 and October 2023 were retrieved from the Scopus database and analyzed using bibliometric tools, including Biblioshiny and VOSviewer, to assess publication output, citation patterns, authorship, institutional and national productivity, and conceptual structure. The results demonstrated a steady growth in PTZ-related publications over time, with China emerging as the leading contributor in terms of publication volume, while Poland showed a high degree of international collaboration. The most cited study was the work by Baraban et al. investigating PTZ-induced behavioral and neural changes in zebrafish. Epilepsy and Behavior, Epilepsy Research, and Epilepsia were identified as the most productive journals in this field. Keyword and thematic analyses revealed frequently studied topics such as oxidative stress, anticonvulsant activity, and neuroinflammation, along with emerging research interests including brain-derived neurotrophic factor and neuronal damage. This study represents the first bibliometric evaluation specifically focused on the PTZ-induced experimental epilepsy model and provides a comprehensive overview of the global research landscape. The findings may assist researchers in recognizing key contributors, identifying research gaps, and guiding future experimental studies in epilepsy.
- 29 April 2026
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 47 (2) , 216-222
Clonidine Attenuates Oxidative Stress Induced by H₂O₂ in C6 Glial Cells
Oxidative stress plays a critical role in the pathogenesis of neurodegenerative diseases and glioma progression, with glial cells being central to maintaining redox homeostasis. Clonidine, an α2-adrenergic and imidazoline receptor agonist, has demonstrated neuroprotective and antioxidant effects in various experimental models. This study aimed to evaluate the protective effects of clonidine against hydrogen peroxide (H₂O₂)-induced oxidative damage in C6 glial cells. C6 glioma cells were pretreated with clonidine (0.3–4.8 µM) for 1 hour, followed by exposure to 0.5 mM H₂O₂ for 24 hours, and cell viability was assessed using the XTT assay, while total antioxidant status (TAS), total oxidant status (TOS), and superoxide dismutase (SOD) levels were measured using commercial kits and ELISA. H₂O₂ exposure significantly reduced cell viability and antioxidant parameters while increasing oxidative markers; however, clonidine treatment significantly improved cell viability, elevated TAS and SOD levels, and decreased TOS levels compared to the H₂O₂ group, demonstrating its dose-dependent protective effect against oxidative stress. These findings suggest that clonidine mitigates oxidative damage in C6 glial cells, potentially through antioxidant, anti-inflammatory, and imidazoline receptor-mediated mechanisms, and may have therapeutic relevance in conditions characterized by glial oxidative stress, including neurodegenerative diseases and glioma.
- 29 April 2026
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 47 (2) , 216-222
Clonidine Attenuates Oxidative Stress Induced by H₂O₂ in C6 Glial Cells
Oxidative stress plays a critical role in the pathogenesis of neurodegenerative diseases and glioma progression, with glial cells being central to maintaining redox homeostasis. Clonidine, an α2-adrenergic and imidazoline receptor agonist, has demonstrated neuroprotective and antioxidant effects in various experimental models. This study aimed to evaluate the protective effects of clonidine against hydrogen peroxide (H₂O₂)-induced oxidative damage in C6 glial cells. C6 glioma cells were pretreated with clonidine (0.3–4.8 µM) for 1 hour, followed by exposure to 0.5 mM H₂O₂ for 24 hours, and cell viability was assessed using the XTT assay, while total antioxidant status (TAS), total oxidant status (TOS), and superoxide dismutase (SOD) levels were measured using commercial kits and ELISA. H₂O₂ exposure significantly reduced cell viability and antioxidant parameters while increasing oxidative markers; however, clonidine treatment significantly improved cell viability, elevated TAS and SOD levels, and decreased TOS levels compared to the H₂O₂ group, demonstrating its dose-dependent protective effect against oxidative stress. These findings suggest that clonidine mitigates oxidative damage in C6 glial cells, potentially through antioxidant, anti-inflammatory, and imidazoline receptor-mediated mechanisms, and may have therapeutic relevance in conditions characterized by glial oxidative stress, including neurodegenerative diseases and glioma.
- 27 February 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (3) , 1461-1474
Synergistic Anticancer Effects of the PLK1 Inhibitor BI-2536 and β-Glucan in Colon and Gastric Cancer Cells
Colon and gastric cancers are among the most prevalent gastrointestinal malignancies, often exhibiting poor prognosis due to resistance and recurrence. Polo-like kinase 1 (PLK1), a key regulator of mitosis, is frequently overexpressed in these cancers. BI-2536, a selective PLK1 inhibitor, has shown promising anticancer activity. β-Glucan, a natural immunomodulator, has also demonstrated anticancer potential. This study aimed to evaluate the antiproliferative, apoptotic, and cell cycle effects of BI-2536 alone and in combination with β-glucan on HT-29 colon and AGS gastric cancer cell lines. Cell viability was assessed using the XTT assay. Apoptosis and cell cycle profiles were evaluated using flow cytometry. The combination index (CI) was calculated using the Chou-Talalay method via CompuSyn software. BI-2536 significantly inhibited proliferation and induced G2/M arrest and apoptosis in both cell lines. β-Glucan showed moderate cytotoxicity and enhanced BI-2536's effects. Synergistic antiproliferative activity was observed at lower drug concentrations, such as 2-16 nM BI-2536 combined with 31.25-250 μg/ml β-glucan (CI2/M arrest compared with either agent alone, demonstrating a clear synergistic effect. BI-2536 in combination with β-glucan exhibits synergistic anticancer effects in vitro, suggesting a promising strategy for treating colon and gastric cancers.
- 27 February 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (3) , 1461-1474
Synergistic Anticancer Effects of the PLK1 Inhibitor BI-2536 and β-Glucan in Colon and Gastric Cancer Cells
Colon and gastric cancers are among the most prevalent gastrointestinal malignancies, often exhibiting poor prognosis due to resistance and recurrence. Polo-like kinase 1 (PLK1), a key regulator of mitosis, is frequently overexpressed in these cancers. BI-2536, a selective PLK1 inhibitor, has shown promising anticancer activity. β-Glucan, a natural immunomodulator, has also demonstrated anticancer potential. This study aimed to evaluate the antiproliferative, apoptotic, and cell cycle effects of BI-2536 alone and in combination with β-glucan on HT-29 colon and AGS gastric cancer cell lines. Cell viability was assessed using the XTT assay. Apoptosis and cell cycle profiles were evaluated using flow cytometry. The combination index (CI) was calculated using the Chou-Talalay method via CompuSyn software. BI-2536 significantly inhibited proliferation and induced G2/M arrest and apoptosis in both cell lines. β-Glucan showed moderate cytotoxicity and enhanced BI-2536's effects. Synergistic antiproliferative activity was observed at lower drug concentrations, such as 2-16 nM BI-2536 combined with 31.25-250 μg/ml β-glucan (CI2/M arrest compared with either agent alone, demonstrating a clear synergistic effect. BI-2536 in combination with β-glucan exhibits synergistic anticancer effects in vitro, suggesting a promising strategy for treating colon and gastric cancers.
- 5 January 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-13
Metformin attenuates PTZ-Induced seizures and cognitive impairment and is associated with altered NOS/NO signaling: combined in vivo and in silico evidence
Epilepsy remains a major neurological disorder with high rates of drug resistance and cognitive decline. Repurposing neuroprotective drugs offers a promising approach. Metformin, a widely used antidiabetic agent, has shown anticonvulsant effects, yet its impact on nitric oxide synthase (NOS) isoforms in distinct brain regions remains unclear. Adult male Wistar rats were allocated into control, pentylenetetrazole (PTZ), or metformin+PTZ groups. Metformin (200 mg/kg, i.p.) was administered for 7 days before induction of acute PTZ seizures (45 mg/kg, i.p.). Seizure severity and latency were assessed using Racine's scale, and cognition was evaluated by the passive avoidance test (PAT). Nitric oxide (NO) and the expression of its synthesizing enzymes, inducible (iNOS), neuronal (nNOS), and endothelial (eNOS), were quantified in the cortex and hippocampus via enzyme-linked immunosorbent assay (ELISA). In silico analyses included target prediction and molecular docking to assess metformin - NOS interactions. Metformin significantly reduced seizure severity, prolonged latency to the first myoclonic jerk, and prevented PTZ-induced memory impairment (all p < 0.001). These behavioral effects were accompanied by reductions in cortical and hippocampal nNOS and iNOS expression, decreased cortical eNOS levels, and lower NO accumulation. TargetNet predicted NOS isoforms among potential metformin targets, and docking indicated moderate binding affinity (-5.2 to -5.9 kcal/mol). Metformin exerted seizure-suppressing and cognition-preserving effects in an acute PTZ model, associated with reductions in NOS isoform expression and NO levels, suggesting altered NOS/NO signaling and supporting its potential as an adjunctive candidate for mitigating seizure-related neuronal dysfunction.
- 5 January 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-13
Metformin attenuates PTZ-Induced seizures and cognitive impairment and is associated with altered NOS/NO signaling: combined in vivo and in silico evidence
Epilepsy remains a major neurological disorder with high rates of drug resistance and cognitive decline. Repurposing neuroprotective drugs offers a promising approach. Metformin, a widely used antidiabetic agent, has shown anticonvulsant effects, yet its impact on nitric oxide synthase (NOS) isoforms in distinct brain regions remains unclear. Adult male Wistar rats were allocated into control, pentylenetetrazole (PTZ), or metformin+PTZ groups. Metformin (200 mg/kg, i.p.) was administered for 7 days before induction of acute PTZ seizures (45 mg/kg, i.p.). Seizure severity and latency were assessed using Racine's scale, and cognition was evaluated by the passive avoidance test (PAT). Nitric oxide (NO) and the expression of its synthesizing enzymes, inducible (iNOS), neuronal (nNOS), and endothelial (eNOS), were quantified in the cortex and hippocampus via enzyme-linked immunosorbent assay (ELISA). In silico analyses included target prediction and molecular docking to assess metformin - NOS interactions. Metformin significantly reduced seizure severity, prolonged latency to the first myoclonic jerk, and prevented PTZ-induced memory impairment (all p < 0.001). These behavioral effects were accompanied by reductions in cortical and hippocampal nNOS and iNOS expression, decreased cortical eNOS levels, and lower NO accumulation. TargetNet predicted NOS isoforms among potential metformin targets, and docking indicated moderate binding affinity (-5.2 to -5.9 kcal/mol). Metformin exerted seizure-suppressing and cognition-preserving effects in an acute PTZ model, associated with reductions in NOS isoform expression and NO levels, suggesting altered NOS/NO signaling and supporting its potential as an adjunctive candidate for mitigating seizure-related neuronal dysfunction.
- Open Access
- 31 July 2025
- Published by Springer Nature in Research Square
Anticancer Activity of PLK1 Inhibitor BI-2536 and β-Glucan in HT-29 and AGS Cancer Cell Lines
Background: Colon and gastric cancers are among the most prevalent gastrointestinal malignancies, often exhibiting poor prognosis due to resistance and recurrence. Polo-like kinase 1 (PLK1), a key regulator of mitosis, is frequently overexpressed in these cancers. BI-2536, a selective PLK1 inhibitor, has shown promising anticancer activity. β-glucan, a natural immunomodulator, has also demonstrated anticancer potential. Objective: This study aimed to evaluate the antiproliferative, apoptotic, and cell cycle effects of BI-2536 alone and in combination with β-glucan on HT-29 colon and AGS gastric cancer cell lines. Methods: Cell viability was assessed by XTT assay. Apoptosis and cell cycle profiles were evaluated by flow cytometry. The combination index (CI) was calculated using the Chou–Talalay method via CompuSyn software. Results: BI-2536 significantly inhibited proliferation and induced G2/M arrest and apoptosis in both cell lines. β-glucan showed moderate cytotoxicity and enhanced BI-2536’s effects in combination. Synergistic antiproliferative activity was observed at lower drug concentrations (CI < 1), with the combination inducing greater apoptosis and G2/M arrest than monotherapy. Mechanistically, this synergy may involve dual restoration of FOXO3 activity via PLK1 inhibition and PI3K/AKT/mTOR suppression. Conclusion: BI-2536 in combination with β-glucan exhibits synergistic anticancer effects in vitro, suggesting a promising strategy for treating colon and gastric cancers. Further in vivo studies are warranted.
- 31 July 2025
- Published by Springer Nature in Research Square
Open AccessAnticancer Activity of PLK1 Inhibitor BI-2536 and β-Glucan in HT-29 and AGS Cancer Cell Lines
Background: Colon and gastric cancers are among the most prevalent gastrointestinal malignancies, often exhibiting poor prognosis due to resistance and recurrence. Polo-like kinase 1 (PLK1), a key regulator of mitosis, is frequently overexpressed in these cancers. BI-2536, a selective PLK1 inhibitor, has shown promising anticancer activity. β-glucan, a natural immunomodulator, has also demonstrated anticancer potential. Objective: This study aimed to evaluate the antiproliferative, apoptotic, and cell cycle effects of BI-2536 alone and in combination with β-glucan on HT-29 colon and AGS gastric cancer cell lines. Methods: Cell viability was assessed by XTT assay. Apoptosis and cell cycle profiles were evaluated by flow cytometry. The combination index (CI) was calculated using the Chou–Talalay method via CompuSyn software. Results: BI-2536 significantly inhibited proliferation and induced G2/M arrest and apoptosis in both cell lines. β-glucan showed moderate cytotoxicity and enhanced BI-2536’s effects in combination. Synergistic antiproliferative activity was observed at lower drug concentrations (CI < 1), with the combination inducing greater apoptosis and G2/M arrest than monotherapy. Mechanistically, this synergy may involve dual restoration of FOXO3 activity via PLK1 inhibition and PI3K/AKT/mTOR suppression. Conclusion: BI-2536 in combination with β-glucan exhibits synergistic anticancer effects in vitro, suggesting a promising strategy for treating colon and gastric cancers. Further in vivo studies are warranted.
- 1 July 2023
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 101 (7) , 361-368
Anticancer activity of sinapic acid by inducing apoptosis in HT-29 human colon cancer cell line
Colorectal cancer is the third most lethal and fourth most commonly diagnosed cancer worldwide. Sinapic acid, a derivative of hydroxycinnamic acid, is a promising phytochemical exhibiting numerous pharmacological activities in various systems. It is a substantial chain-breaking antioxidant that operates as a radical scavenger. The aim of this research was to investigate the antiproliferative effect of sinapic acid on the HT-29 cell line besides the mechanisms underlying this activity. The effect of sinapic acid on the viability of HT-29 cell line was investigated using XTT assay. The levels of BCL-2, cleaved caspase 3, BAX, cleaved PARP, and 8-oxo-dG were measured using ELISA. Gamma-H2AX and cytochrome c expressions were assessed semiquantitatively using immunofluorescence staining. Sinapic acid at 200 µm and higher doses produced a significant antiproliferative effect on HT-29 cells. The IC50 value was found to be 317.5 µm for 24 h. Sinapic acid (317.5 µm) significantly elevated cleaved caspase 3, BAX, cleaved PARP, and 8-oxo-dG levels. The levels of gamma-H2AX foci are significantly higher, while the levels of cytochrome c are lower in sinapic acid-treated HT-29 cells. These results indicate that sinapic acid has antiproliferative, apoptotic, and genotoxic effects on colon cancer cells.
- 1 July 2023
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 101 (7) , 361-368
Anticancer activity of sinapic acid by inducing apoptosis in HT-29 human colon cancer cell line
Colorectal cancer is the third most lethal and fourth most commonly diagnosed cancer worldwide. Sinapic acid, a derivative of hydroxycinnamic acid, is a promising phytochemical exhibiting numerous pharmacological activities in various systems. It is a substantial chain-breaking antioxidant that operates as a radical scavenger. The aim of this research was to investigate the antiproliferative effect of sinapic acid on the HT-29 cell line besides the mechanisms underlying this activity. The effect of sinapic acid on the viability of HT-29 cell line was investigated using XTT assay. The levels of BCL-2, cleaved caspase 3, BAX, cleaved PARP, and 8-oxo-dG were measured using ELISA. Gamma-H2AX and cytochrome c expressions were assessed semiquantitatively using immunofluorescence staining. Sinapic acid at 200 µm and higher doses produced a significant antiproliferative effect on HT-29 cells. The IC50 value was found to be 317.5 µm for 24 h. Sinapic acid (317.5 µm) significantly elevated cleaved caspase 3, BAX, cleaved PARP, and 8-oxo-dG levels. The levels of gamma-H2AX foci are significantly higher, while the levels of cytochrome c are lower in sinapic acid-treated HT-29 cells. These results indicate that sinapic acid has antiproliferative, apoptotic, and genotoxic effects on colon cancer cells.
- Open Access
- 26 March 2023
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 44 (1) , 41-45
Investigation of the Analgesic Properties L-759,633 and SER 601 in Experimental Neuropathic Pain Model in Rats and their Comparison with Pregabalin
Despite the fact that narcotics and NSAIDs are the mainstays of nociceptive pain care, only a small proportion of neuropathic pain patients benefit from them. Cannabinoid agents could be a viable alternative to opioids in the management of chronic pain. The goal of our investigation was to assess the analgesic efficacy of SER 601 and L-759,633, cannabinoid receptor 2 (CB2) agonists, at various doses in a model of neuropathic pain generated in rat. The analgesic effect of CB2 agonists L-759,633 and SER 601 at various doses in a rat model of neuropathic pain created by partial sciatic nerve ligation was examined by the hot plate method. Furthermore, a comparison of analgesic effects of both drugs with pregabalin is also conducted. The two substances demonstrated a dose-dependent analgesic effect in this model. The analgesic response of SER601 and L-759,633 in the neuropathic pain model was higher compared to that of pregabalin. All in all, our data suggest that SER601 and L-759,633 may offer a beneficial treatment option for neuropathic pain in future.
- 26 March 2023
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 44 (1) , 41-45
Open AccessInvestigation of the Analgesic Properties L-759,633 and SER 601 in Experimental Neuropathic Pain Model in Rats and their Comparison with Pregabalin
Despite the fact that narcotics and NSAIDs are the mainstays of nociceptive pain care, only a small proportion of neuropathic pain patients benefit from them. Cannabinoid agents could be a viable alternative to opioids in the management of chronic pain. The goal of our investigation was to assess the analgesic efficacy of SER 601 and L-759,633, cannabinoid receptor 2 (CB2) agonists, at various doses in a model of neuropathic pain generated in rat. The analgesic effect of CB2 agonists L-759,633 and SER 601 at various doses in a rat model of neuropathic pain created by partial sciatic nerve ligation was examined by the hot plate method. Furthermore, a comparison of analgesic effects of both drugs with pregabalin is also conducted. The two substances demonstrated a dose-dependent analgesic effect in this model. The analgesic response of SER601 and L-759,633 in the neuropathic pain model was higher compared to that of pregabalin. All in all, our data suggest that SER601 and L-759,633 may offer a beneficial treatment option for neuropathic pain in future.
- 27 June 2022
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 19 (3) , 336-342
Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain
Drugs that inhibit the reuptake of serotonin, norepinephrine, and/or dopamine are widely used for treating depressive disorders and have emerged as effective drugs for neuropathic pain. They have no substantial anti-nociceptive effects but are considered, with gabapentin/pregabalin, first-line drugs for neuropathic pain. In this study, three different antidepressant agents were used in different doses to investigate their anti-hyperalgesic effects in rat models of neuropathic pain using hot plate and tail flick methods. They have different mechanisms of action; vilazodone hydrochloride is a selective serotonin inhibitor and a 5-HT1A partial agonist; talsupram hydrochloride is a selective noradrenaline inhibitor, and it has a high affinity for noradrenaline transporter (NET), whereas indatraline hydrochloride is a triple reuptake inhibitor that inhibits transporters for 5-HT (SERT), dopamine (DAT), and NET. All the drugs used in the experiment were found to have an anti-hyperalgesic effect in both tests compared to the sham group. When anti-hyperalgesic effects of the three agents were compared to each other, it was found that talsupram hydrochloride was significantly more effective than the two other drugs in hot plate test. However, there was no statistically significant difference in the tail flick test. Indatraline hydrochloride was more effective than vilazodone hydrochloride at the same doses in the tail flick test. Our data suggest that three drugs are effective analgesics in rat models of neuropathic pain and inhibition of noradrenaline reuptake represents the cornerstone of analgesic mechanisms of effective antidepressants.
- 27 June 2022
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 19 (3) , 336-342
Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain
Drugs that inhibit the reuptake of serotonin, norepinephrine, and/or dopamine are widely used for treating depressive disorders and have emerged as effective drugs for neuropathic pain. They have no substantial anti-nociceptive effects but are considered, with gabapentin/pregabalin, first-line drugs for neuropathic pain. In this study, three different antidepressant agents were used in different doses to investigate their anti-hyperalgesic effects in rat models of neuropathic pain using hot plate and tail flick methods. They have different mechanisms of action; vilazodone hydrochloride is a selective serotonin inhibitor and a 5-HT1A partial agonist; talsupram hydrochloride is a selective noradrenaline inhibitor, and it has a high affinity for noradrenaline transporter (NET), whereas indatraline hydrochloride is a triple reuptake inhibitor that inhibits transporters for 5-HT (SERT), dopamine (DAT), and NET. All the drugs used in the experiment were found to have an anti-hyperalgesic effect in both tests compared to the sham group. When anti-hyperalgesic effects of the three agents were compared to each other, it was found that talsupram hydrochloride was significantly more effective than the two other drugs in hot plate test. However, there was no statistically significant difference in the tail flick test. Indatraline hydrochloride was more effective than vilazodone hydrochloride at the same doses in the tail flick test. Our data suggest that three drugs are effective analgesics in rat models of neuropathic pain and inhibition of noradrenaline reuptake represents the cornerstone of analgesic mechanisms of effective antidepressants.